All Phenotypes Pard3<tm1Shoh> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh	either: FVB.129-Pard3^tm1Shoh Krt14^tm1(cre)Wbm or (involves: 129P2/OlaHsd * 129S4/SvJae)	MGI:6258533
cn2	Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(HIST1H2BB/EGFP)1Pa/0	involves: 129 * C57BL/6J	MGI:6272614
cn3	Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J	MGI:6272603
cn4	Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(Mt1-Hgf)#Lmb/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J	MGI:6272611

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:192905 )

N	• untreated mice are viable and reach adulthood with no development of spontaneous skin tumors

decreased incidence of tumors by chemical induction ( J:192905 )

• in a 2-stage DMBA/TPA skin carcinogenesis model, papilloma formation is delayed by ~3 weeks, tumor multiplicity is strongly reduced, and tumors that do form grow slower than in similarly treated wild-type controls

increased incidence of tumors by chemical induction ( J:192905 )

• in a 2-stage DMBA/TPA skin carcinogenesis model, mice show increased incidence of keratoacanthomas (KAs) with typical crater-like morphology, broad tumor base and a keratin-filled center, and tumor sizes that reach >1 cm by 22 weeks post-initiation requiring termination

• at termination, 91% of DMBA/TPA mice are KA-positive versus 27% of wild-type controls

• however, incidence of squamous cell carcinomas (SCCs) is relatively normal

increased metastatic potential ( J:192905 )

• 45% of the relatively small papillomas found in in DMBA/TPA-treated mice show local invasion of tumor cells into the stroma versus 33% of the abundant larger papillomas found in wild-type controls

• 36% of keratoacanthomas (KAs) found in in DMBA/TPA-treated show local invasion into the stroma versus 0% of the KAs found in wild-type controls

decreased tumor growth/size ( J:192905 )

• in response to DMBA/TPA treatment, papillomas that form grow slower than in wild-type controls

• at 14.5 weeks post-DMBA treatment, average papilloma size is significantly smaller than that in wild-type controls

• epidermal cell proliferation is significantly reduced, whereas epidermal apoptosis is significantly increased relative to wild-type controls

increased tumor growth/size ( J:192905 )

• at 22 weeks post-DMBA treatment, keratoacanthomas reach an average size of >1 cm, unlike in wild-type controls

decreased tumor latency ( J:192905 )

• DMBA/TPA-treated mice show accelerated appearance of keratoacanthomas relative to wild-type controls, with KAs first detected at 7 weeks post-DMBA treatment

increased tumor latency ( J:192905 )

• in DMBA/TPA-treated mice, papilloma formation is delayed by ~3 weeks relative to wild-type controls

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:192905 )

increased incidence of tumors by chemical induction ( J:192905 )

• at termination, 91% of DMBA/TPA mice are KA-positive versus 27% of wild-type controls

• however, incidence of squamous cell carcinomas (SCCs) is relatively normal

Allelic Composition	Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(HIST1H2BB/EGFP)1Pa/0
Genetic Background	involves: 129 * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krt14^tm1(cre)Wbm mutation (0 available); any Krt14 mutation (36 available)
Pard3^tm1Shoh mutation (0 available); any Pard3 mutation (96 available)
Tg(HIST1H2BB/EGFP)1Pa mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

pigmentation

abnormal melanocyte morphology ( J:240961 )

• in P58 tail whole mounts, melanocytes (MCs) show a more stubby dendritic morphology with dendritic shortening and a more spread cell body area relative to MCs in control mice

Allelic Composition	Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:240961 )

• in a 2-stage DMBA/TPA skin carcinogenesis model, mice show increased melanocytic hyperplasia and incidence of melanoma relative to control mice

pigmentation

abnormal hair follicle melanocyte morphology ( J:240961 )

• under non-tumorigenic conditions, mice show a significant increase in melanocyte number per hair follicle in back skin relative to control mice at P0, at 7 weeks, and at 4 and 12 months of age

• both the number of P-cadherin-positive keratinocytes in interfollicular epidermis and melanocyte number contacting dense P-cadherin-positive cell clusters in developing hair follicles are significantly increased relative to controls

abnormal epidermal melanocyte morphology ( J:240961 )

• under non-tumorigenic conditions, newborn (P0) mice show a significant increase in interfollicular melanocytes in back skin relative to control mice

• P-cadherin-positive clusters are enlarged in interfollicular epidermis, with frequent localization of melanocytes to these compartments

increased melanocyte number ( J:240961 )

• in a 2-stage DMBA/TPA skin carcinogenesis model, mice show increased melanocytic hyperplasia in the epidermis relative to control mice

• under non-tumorigenic conditions, mice show a significantly higher melanocyte number in back skin relative to control mice at P0 and all adult ages tested

integument

abnormal hair follicle melanocyte morphology ( J:240961 )

• under non-tumorigenic conditions, mice show a significant increase in melanocyte number per hair follicle in back skin relative to control mice at P0, at 7 weeks, and at 4 and 12 months of age

abnormal epidermal melanocyte morphology ( J:240961 )

• under non-tumorigenic conditions, newborn (P0) mice show a significant increase in interfollicular melanocytes in back skin relative to control mice

• P-cadherin-positive clusters are enlarged in interfollicular epidermis, with frequent localization of melanocytes to these compartments

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:240961 )

• in a 2-stage DMBA/TPA skin carcinogenesis model, mice show increased melanocytic hyperplasia and incidence of melanoma relative to control mice

Allelic Composition	Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(Mt1-Hgf)#Lmb/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4^tm1.1Bbd mutation (0 available); any Cdk4 mutation (57 available)
Krt14^tm1(cre)Wbm mutation (0 available); any Krt14 mutation (36 available)
Pard3^tm1Shoh mutation (0 available); any Pard3 mutation (96 available)
Tg(Mt1-Hgf)#Lmb mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:240961 )

• at 8-15 weeks after DMBA treatment, mice exhibit significantly increased melanoma multiplicity relative to control mice, with primary melanomas invading the dermis and showing tumor-associated angiogenesis

increased metastatic potential ( J:240961 )

• less than 15 weeks after DMBA treatment, mice show increased incidence of distal melanoma metastases in the lungs relative to control mice (57.1% versus 16.7%)

increased tumor growth/size ( J:240961 )

• in DMBA-treated mice, primary melanomas show an increased proliferative index, with a significantly higher number of PCNA^high melanoma cells relative to control mice, consistent with increased melanoma multiplicity

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:240961 )

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23